Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Olfactory Receptors: Location and Structure01:03

Olfactory Receptors: Location and Structure

11.1K
The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
11.1K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.3K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.3K
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

2.7K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
2.7K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Drugs Acting on Autonomic Ganglia: Blockers01:28

Drugs Acting on Autonomic Ganglia: Blockers

1.6K
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups:
1.6K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

884
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
884

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of the extent of previous endoscopic sinus surgery using the ACCESS score in patients with chronic rhinosinusitis referred to tertiary care rhinologic clinics.

Rhinology·2026
Same author

Regional disparities in cost-effectiveness of biologics for CRSwNP should not modify the strategy.

Rhinology·2026
Same author

Olfactory implants: international opinion paper on emerging technologies and clinical applications.

Rhinology·2025
Same author

Granulocyte Colony Stimulating Factor (G-CSF) and Olfactory Function-A Clinical Pilot Study.

Laryngoscope investigative otolaryngology·2025
Same author

The extra cost of biologics as first-line treatment in uncontrolled chronic rhinosinusitis with nasal polyps with no previous sinus surgery is overwhelming: a budget impact analysis.

Rhinology·2025
Same author

Position paper on olfactory dysfunction: 2023

Rhinology·2023

Related Experiment Video

Updated: Jan 13, 2026

A Lateralized Odor Learning Model in Neonatal Rats for Dissecting Neural Circuitry Underpinning Memory Formation
10:42

A Lateralized Odor Learning Model in Neonatal Rats for Dissecting Neural Circuitry Underpinning Memory Formation

Published on: August 18, 2014

9.3K

Neuromodulators do not appear effective for post-viral parosmia.

K Resler1,2, B R Castro3, Z M Patel2

  • 1Department and Clinic of Otolaryngology, Head and Neck Surgery, Wroclaw Medical University, Wroclaw, Poland.

Rhinology
|January 7, 2026
PubMed
Summary
This summary is machine-generated.

Post-viral smell distortion, or parosmia, significantly impacts quality of life. Current treatments effectively address quantitative smell loss but lack high-level evidence for qualitative olfactory disorders.

More Related Videos

Selective Viral Transduction of Adult-born Olfactory Neurons for Chronic in vivo Optogenetic Stimulation
12:00

Selective Viral Transduction of Adult-born Olfactory Neurons for Chronic in vivo Optogenetic Stimulation

Published on: December 28, 2011

15.9K
Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
15:04

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

11.4K

Related Experiment Videos

Last Updated: Jan 13, 2026

A Lateralized Odor Learning Model in Neonatal Rats for Dissecting Neural Circuitry Underpinning Memory Formation
10:42

A Lateralized Odor Learning Model in Neonatal Rats for Dissecting Neural Circuitry Underpinning Memory Formation

Published on: August 18, 2014

9.3K
Selective Viral Transduction of Adult-born Olfactory Neurons for Chronic in vivo Optogenetic Stimulation
12:00

Selective Viral Transduction of Adult-born Olfactory Neurons for Chronic in vivo Optogenetic Stimulation

Published on: December 28, 2011

15.9K
Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols
15:04

Modeling and Simulations of Olfactory Drug Delivery with Passive and Active Controls of Nasally Inhaled Pharmaceutical Aerosols

Published on: May 20, 2016

11.4K

Area of Science:

  • Neurology
  • Otolaryngology
  • Infectious Disease

Background:

  • The COVID-19 pandemic highlighted post-viral smell distortion, known as parosmia, a qualitative dysfunction impacting odor perception.
  • Parosmia involves distorted smell perception, often co-occurring with quantitative olfactory loss, severely affecting patients' quality of life.
  • While treatments exist for quantitative smell loss, effective interventions for qualitative olfactory disorders remain unproven.

Purpose of the Study:

  • To review the current landscape of treatments for olfactory dysfunction.
  • To specifically address the lack of high-level evidence for treating qualitative olfactory disorders like parosmia.

Main Methods:

  • Literature review of existing studies on olfactory dysfunction treatments.
  • Analysis of evidence supporting interventions for both quantitative and qualitative smell disorders.

Main Results:

  • Olfactory training, steroid nasal irrigations, and platelet-rich plasma injections show promise for quantitative smell loss.
  • No high-level evidence currently supports effective treatments specifically for qualitative olfactory disorders such as parosmia.

Conclusions:

  • Effective treatments for quantitative smell loss are established, but qualitative olfactory disorders like parosmia remain challenging.
  • Further research is needed to develop and validate treatments for parosmia and other qualitative smell dysfunctions.